Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. - Wikidata - awgldk - TriplyDB

Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac.

Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac.

http://www.wikidata.org/entity/Q39168921

about

Daclizumab therapy for multiple sclerosis Ciclosporin A proof of concept study in patients with active, progressive HTLV-1 associated myelopathy/tropical spastic paraparesis Treatment of HTLV-I-Associated Myelopathy / Tropical Spastic Paraparesis: Towards Rational Targeted Therapy The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.Immunopathogenesis of HTLV-I-associated myelopathy/tropical spastic paraparesis.Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP Immunotherapy for ovarian cancer: what's next?The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Common γ-chain blocking peptide reduces in vitro immune activation markers in HTLV-1-associated myelopathy/tropical spastic paraparesis.Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.Cytokine Therapies in Neurological Disease.Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.Inflammatory manifestations of HTLV-1 and their therapeutic options.A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.Pathogenesis and treatment of human T-cell lymphotropic virus Type I-associated myelopathy.Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.The NK cell as a new player in the pathogenesis of HTLV-I associated neurologic disease Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin.Daclizumab Therapy for Multiple Sclerosis.

P2860

Q27022517-49A08CFE-74A0-4D53-B540-86A7AD91B0A8 Q28484214-9FC4E41C-CFBB-48F8-A6F6-EC4B7017B0D6 Q28972318-871F06B5-4B7D-4CE2-8579-4267DE7FB137 Q30730505-C8388AF2-0138-45E1-953B-7446155EF951 Q34157538-2192B921-0FCF-4B5B-83C2-72CB6156C16F Q34596171-D47D7A72-C0C3-4021-9C3A-E31FD959BF8C Q34667760-C94AFDE6-49C8-46BE-911E-CCDF5771CE2B Q34743514-104EC4B8-A704-400E-9CEC-03752F189B6C Q35058213-EDA0A265-128F-4F83-BB5A-578D2B6FACC9 Q36055527-607A6C4B-155A-4330-BC32-F6C5C9B2D225 Q36832132-FAB63E92-390C-44BB-8831-2EEEDF935C2B Q37136498-07C6F448-5351-4DE3-A12B-693F9E1035E5 Q37968620-FAE7310A-C82B-432A-B9B9-87E99621CAD1 Q38262169-1204307C-D680-447A-8289-5CD94FF6A06E Q38397484-E56B772F-784E-4100-A95A-F7A75BC13A08 Q39289873-67DB0341-5342-472E-9E79-030C7AEDFF03 Q39434495-E2290988-7642-46F0-9226-38CF1C8F5050 Q42720021-7BEBC887-BCE8-43E6-B07D-272851AB6A0C Q43905322-BCB34184-005B-4B90-98D3-B6BEF16F524E Q47959279-FB8654E7-2BCF-47DB-A111-7A0BB6397478 Q51975777-8AE0E60C-146F-46DC-8CA1-501D12C356CD Q52319805-DFECF306-0DBD-4FED-A5D7-B3270A61BAC4

P2860

Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac.

http://www.wikidata.org/entity/Q39168921

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

1998年论文

@zh

1998年论文

@zh-cn

name

Reduction in HTLV-I proviral l ...... eated with humanized anti-Tac.

@en

Reduction in HTLV-I proviral l ...... eated with humanized anti-Tac.

@nl

type

label

Reduction in HTLV-I proviral l ...... eated with humanized anti-Tac.

@en

Reduction in HTLV-I proviral l ...... eated with humanized anti-Tac.

@nl

prefLabel

Reduction in HTLV-I proviral l ...... eated with humanized anti-Tac.

@en

Reduction in HTLV-I proviral l ...... eated with humanized anti-Tac.

@nl

P1433

Q39168921-F208856F-2E6D-4A81-8F85-4426D7D6009A

P1476

Q39168921-8964983B-963D-466A-A651-2D1F78B67DD8

P2093

Q39168921-007E1CA5-3AED-4EDA-B485-C880DFD38EA2

Q39168921-277C584A-E8BE-4B53-B48F-671937C98F82

Q39168921-30A893D8-C64B-4328-AA4A-713438AFD7C4

Q39168921-3D8DCC48-5157-496D-B3AD-E8CF4E9E4412

Q39168921-6EE59C96-9BD8-4FBE-A21C-3041FE9950C8

Q39168921-7C009FC4-478C-4488-A013-EFF2909905F3

Q39168921-7E2900B3-CA67-43F9-8F4F-AF1E0469CCCD

Q39168921-7FD93E8B-4A01-416D-8287-28592462F121

Q39168921-869215E3-3D24-4A75-80F0-E95686A4BFC7

Q39168921-AD55B292-EF25-45FE-9BEE-E3BBEA1364FE

P2860

Q39168921-810CF7A5-15A6-4325-B2B3-98683CBB0E52

Q39168921-FFAA0A17-E80B-42E8-BD09-6EF241182DC1

P304

Q39168921-11B3C6D7-E0E3-4F6E-8B7F-47658D18F3B9

P31

Q39168921-9C23917A-BFCB-46E9-A35D-0CC847336248

P356

Q39168921-AB177041-FA56-4F26-83EF-17A78ACA1009

P433

Q39168921-BEBE3714-B144-4651-BA12-D55B1848C7F0

P478

Q39168921-8DFD1A89-4ED7-4363-BEEF-ACD109C768D6

P577

Q39168921-A26BBB96-3576-4FAC-8A6B-C9889FBDAF7A

P698

Q39168921-9FC41030-9844-42B1-A4E8-BA696303C3E7

P921

Q39168921-CBAAF976-DCCB-4350-AD4E-2AAFFC5B1E83

P356

P1433

Annals of Neurology

P1476

Reduction in HTLV-I proviral l ...... eated with humanized anti-Tac.

@en

P2093

Bamford RN

http://www.w3.org/2001/XMLSchema#string

Brown M

http://www.w3.org/2001/XMLSchema#string

Fleisher TA

http://www.w3.org/2001/XMLSchema#string

Flerlage AN

http://www.w3.org/2001/XMLSchema#string

Jacobson S

http://www.w3.org/2001/XMLSchema#string

Kubota R

http://www.w3.org/2001/XMLSchema#string

Lehky TJ

http://www.w3.org/2001/XMLSchema#string

Leist TP

http://www.w3.org/2001/XMLSchema#string

Levin MC

http://www.w3.org/2001/XMLSchema#string

Light S

http://www.w3.org/2001/XMLSchema#string

P2860

High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy.

Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy.

P304

942-947

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.410440613

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

1998-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9851439

http://www.w3.org/2001/XMLSchema#string

P921

Human T-lymphotropic virus 1